Hyperparathyroidism Clinical Trial
Parathyroid glands are small endocrine glands that secrete a hormone which controls blood calcium levels. Primary hyperparathyroidism (PH) is a common disorder whereby one or more of these glands may enlarge and overproduce their hormone. Subsequently, the elevated blood calcium can cause many other symptoms and problems. The standard treatment is surgical removal of the gland(s) causing the disorder. The standard safe and effective operation has been the bilateral open parathyroid exploration (BOPE). A newer procedure using a radioactive compound that concentrates in the parathyroid glands allows a more limited operation to find and remove the causative gland [Minimally-Invasive Radioguided Parathyroidectomy (MIRP)]. The radiation exposure is minimal and safe. Although the operation may prove to be less expensive, it is not certain whether it is as effective or as safe as BOPE. This study serves to directly compare the costs, the effectiveness, and the safety associated with each type of operation. All patients (adolescents and older) with PH are candidates to participate. The participants will be randomly assigned to the MIRP group or the BOPE group independently of patient or physician preferences. MIRP patients will undergo a sestamibi nuclear medicine scan to attempt to localize the specific parathyroid gland causing the hyperparathyroidism and subsequently a limited operation under local anesthesia to remove the single gland. Parathyroid hormone levels will be measured during the operation to ensure that the patient has been cured. If not, the standard BOPE procedure will be completed. The total cost of the care will be tracked for each group. Careful testing for complications such as vocal cord dysfunction will be done. General Health status and pain levels will be measured before and after each operation. Patient satisfaction with the operation and care will also be assessed.
n/a
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00377312 -
7 Day Continuous Parathyroid Hormone IV Infusion
|
Phase 0 | |
| Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
| Completed |
NCT04040946 -
Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention
|
Phase 3 | |
| Recruiting |
NCT03053999 -
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
|
||
| Withdrawn |
NCT02711059 -
Insulin Resistance in Primary Hyperparathyroidism
|
N/A | |
| Completed |
NCT01691781 -
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
|
N/A | |
| Completed |
NCT00538720 -
Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)
|
Phase 1 | |
| Completed |
NCT00887666 -
Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure
|
N/A | |
| Terminated |
NCT03044600 -
Gene Expression in Hyperparathyroidism
|
||
| Completed |
NCT03747029 -
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
|
||
| Completed |
NCT01872429 -
Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients
|
N/A | |
| Completed |
NCT00800358 -
Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism
|
N/A | |
| Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
| Completed |
NCT03968510 -
Swalqol in Primary Hyperparathyroidism
|
||
| Completed |
NCT00501215 -
Effect of Parathyroidectomy on Sleep
|
N/A | |
| Completed |
NCT02591160 -
Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism
|
N/A | |
| Recruiting |
NCT05299632 -
F-18 PSMA for Localization of Parathyroid Adenoma
|
||
| Recruiting |
NCT02986607 -
Corticosteroid Rhythms in Hypoparathyroid Patients
|
Early Phase 1 | |
| Completed |
NCT02432599 -
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
|
Phase 2 | |
| Completed |
NCT02524041 -
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism
|
N/A |